BCR and chronic myelogenous leukemia, BCR-ABL1 positive: Dasatinib is a dual BCR/ABL and Src family tyrosine kinase inhibitor approved for chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL) treatment.